Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain

Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain
Enrollment has resumed for Aptinyx's Phase 2 clinical trial of NYX-2925, an oral small molecule designed to treat chronic pain in adults with fibromyalgia, the company announced. The study (NCT04147858) is recommencing after being temporarily suspended in March due to the escalation of COVID-19 in the U.S. Aptinyx has assured patients that the company will take necessary safety precautions to minimize risk to study participants.  “We are very pleased to be restarting this study. It will build on the positive results from our first Phase 2 evaluation of NYX-2925 in patients with fibromyalgia," Norbert Riedel, PhD, Aptinyx's president and CEO, said in a press release
Subscribe or to access all post and page content.